Agios to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025
Agios to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025
CAMBRIDGE, Mass., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that its management team is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 7:30 a.m. PT / 10:30 a.m. ET.
馬薩諸塞州劍橋，2025年1月3日（環球新聞）-- Agios Pharmaceuticals, Inc.（納斯達克：AGIO），一家在細胞代謝和Pk激活領域的領導者，開創了針對罕見疾病的治療方案，今天宣佈其管理團隊計劃在2025年1月15日星期三上午7:30 PT / 上午10:30 ET於第43屆摩根大通醫療會議上進行報告。
The live webcast will be accessible on the Investors section of the company's website () under the "Events & Presentations" tab. A replay of the webcast will be archived on the company's website for at least two weeks following the presentation.
直播網絡廣播將在公司網站的投資者部分（）的「活動與演示」標籤下提供訪問。會議的重播將在公司網站上存檔，至少保存兩週。
About Agios
Agios is the pioneering leader in PK activation and is dedicated to developing and delivering transformative therapies for patients living with rare diseases. In the U.S., Agios markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for this rare, lifelong, debilitating hemolytic anemia. Building on the company's deep scientific expertise in classical hematology and leadership in the field of cellular metabolism and rare hematologic diseases, Agios is advancing a robust clinical pipeline of investigational medicines with programs in alpha- and beta-thalassemia, sickle cell disease, pediatric PK deficiency, myelodysplastic syndromes (MDS)-associated anemia and phenylketonuria (PKU). In addition to its clinical pipeline, Agios is advancing a preclinical TMPRSS6 siRNA as a potential treatment for polycythemia vera. For more information, please visit the company's website at .
關於Agios
Agios是Pk激活的先鋒領導者，致力於開發和提供改變患者生活的治療方案，使他們能夠應對罕見疾病。在美國，Agios爲患有Pk缺乏症的成年人提供一種首創的丙酮酸激酶(PK)激活劑，這是該罕見、終身性和嚴重溶血性貧血的第一種改變疾病進程的治療方案。基於公司在經典血液學領域的深厚科學專業知識以及在細胞代謝和罕見血液病領域的領導地位，Agios正在推進一條強大的臨牀研發管線，涉及α-和β-地中海貧血、鐮狀細胞病、小兒Pk缺乏症、骨髓異常綜合徵(MDS)相關貧血和苯丙酮尿症(PKU)的研究項目。除臨牀管線外，Agios還在推動一種前臨牀TMPRSS6 siRNA作爲治療真性紅細胞增多症的潛在方案。更多信息，請訪問公司的官方網站。
Contacts:
聯繫方式：
Investor Contact
Chris Taylor, VP, Investor Relations and Corporate Communications
Agios Pharmaceuticals
IR@agios.com
投資者聯繫
克里斯·泰勒，副總裁，投資者關係和企業傳播
Agios Pharmaceuticals
IR@agios.com
Media Contact
Eamonn Nolan, Senior Director, Corporate Communications
Agios Pharmaceuticals
Media@agios.com
媒體聯繫人
Eamonn Nolan，高級企業通信董事
Agios Pharmaceuticals
Media@agios.com
